Abstract
The use of recombinant interferons (rIFNs) for myeloproliferative neoplasms (MPNs) has increased significantly in the past 20 years, especially for polycythemia vera (PV) and essential thrombocythemia (ET). In PV, substantial change in the JAK2V617F allele burden (found in virtually all cases of PV and in approximately half of patients with ET) has occurred. 1 Silver R.T. Kiladjian J.J. Hasselbalch H.C. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013; 6: 49-58 Crossref PubMed Scopus (83) Google Scholar This observation has not been consistently noted in patients treated with rIFN-α2b. 2 Jones A.V. Silver R.T. Waghorn K. et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006; 107: 3339-3341 Crossref PubMed Scopus (100) Google Scholar The issue as to whether there is a qualitative or a quantitative difference is relevant for the treatment of ET and PV.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
